Press Release: Cure HHT Plays Key Role in First Successful HHT Trial

We’re thrilled to share some important news from the world of HHT research.

The National Institutes of Health-sponsored PATH trial is complete, the results are in, and it marks an important step forward for HHT treatment and care. This trial was the first positive, large-scale randomized trial for an HHT therapeutic. This study tested the use of the cancer drug pomalidomide in treatment of HHT-related bleeding — and researchers saw very promising results. The data was strong enough that the trial ended early!

But the news gets even better: Now, the full results of the study are published in the New England Journal of Medicine (you can read it here) — one of the most prestigious medical publications in the world, read by more than one million physicians every week. This is a huge win for HHT Awareness, as this publication puts HHT in the spotlight of the medical community.

At Cure HHT, we are the catalyst for driving HHT science forward. We’re proud to have played an important role in advocating for the funding necessary to run this study, and in recruitment to ensure its success.

Read our full press release here and learn more about this milestone below.